Immix Biopharma Investor Presentation Deck

ImmixBio Pipeline: Autoimmune CAR-T Company with 73 patients dosed to-date Stage Clinical Preclinical Tx Type CAR-T TSTX CAR-T CAR-T TSTX TSTX Candidate NXC-201 target BCMA iMX-110 TME Normalization™ Technology NXC-301 NXC-401 iMX-111 iMX-120 Indication AL Amyloidosis Autoimmune Multiple Myeloma Solid Tumors, Colorectal, Soft Tissue Sarcoma + Tislelizumab (anti-PD-1) ALL, LBCL, MCL AML Colorectal Cancer Inflammatory Bowel Disease Preclinical Phase 1b/2a Ongoing IND-enabled Phase 1b/2a Ongoing Phase 1b/2a Ongoing Preclinical Phase 1 Preclinical Preclinical Preclinical Phase 2 Phase 3 Approval Collaboration BeiGene Progress 10 patients treated in relapsed/refractory AL Amyloidosis • 100% overall response rate • 70% complete response rate • Indication to be announced 63 patients treated ● 95% overall response rate ● ● ● US FDA Orphan Drug Designation (ODD) for AL Amyloidosis Granted ● ●●● IMMİX S BIOPHARMA US FDA Orphan Drug Designation (ODD) for Multiple Myeloma Granted US FDA Orphan Drug Designation (ODD) for STS Granted US FDA Rare Pediatric Disease Designation (RPDD) Granted Zero drug-related SAES CMC: 7 GMP batches manufactured to-date In preclinical development EXPAND technology In preclinical development • EXPAND technology Tissue Specific Biologic™ Targeted biomarker GLUT1 overexpressed in stage 3/4 colorectal cancer and additional tumor types Tissue Specific Biologic™ 12-month end-to-end clinical trial leading to potential approval in multi billion-dollar indication Global Rights • 600 * IMMIX fo BIOPHARMA 00 • ** *** do IMMIX BIOPHARMA ** ... +4 do IMMIX BIOPHARMA IMMIX BIOPHARMA IMMIX BIOPHARMA IMMIX BIOPHARMA IMMIX BIOPHARMA BIOPHARMA Note: 95% overall response rate in multiple myeloma isf or patients without prior BCMA targeted therapies. Treatment. Source: Lebel E, et al. Efficacy and Safety of a Locally Produced Novel Anti-BCMA Chimeric Antigen Receptor T-Cell (CART) (HB10101) for the Treatment of Relapsed and Refractory Multiple Myeloma, International Myeloma Society 20th Annual Meeting. 2023. Lebel, E., et al. Feasibility of a Novel Academic Anti-BCMA Chimeric Antigen Receptor T-Cell (CART) (HBI0101) for the Treatment of Relapsed and Refractory AL Amyloidosis. American Society of Hematology 65th Annual Meeting. 2023. Differences exist between trial designs and subject characteristics, and caution should be exercised when comparing data across studies. 30

View entire presentation